CELC·Celcuity Inc.
CELC|Analyst Targets
CELC|Insider Trading
CELC|Fundamentals
CELC|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-1.46 | $-1.33 | +9.0% |
| Q3'25 | $-0.96 | $-0.78 | +18.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | - | $0 | - |
| Q3'25 | - | $0 | - |
CELC|Monthly Returns
Market Data
CELC Stock Snapshot
- Market cap
- 3.16B
- Day range
- $61.71 – $64.60
- News sentiment
- 61/100 · Bullish
- Analyst target
- $150.85 (+134.3%)
- Consensus
- Buy · 21 analysts
Price action on CELC is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.
Sector Rotation
Is money rotating into or out of CELC's sector?
Celcuity Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, CELC ranks 9th of 15 tracked industries, weakening.
- Sector rank
- #2 of 12
- Sector state
- Weakening
- Sector rotation score
- 82
- Industry rank
- #9 of 15
Analyst Consensus Estimates
What do analysts expect CELC to earn?
Analysts expect Celcuity Inc. to earn -$4.39 per share in the fiscal year ending Dec 2026 and $6.56 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on CELC?
HC Wainwright & Co. most recently reiterated its rating on Celcuity Inc. to Buy on Nov 9, 2026 with a price target of $150 (from $155). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- HC Wainwright & Co.: Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in CELC?
Pfizer Inc. reports a stake in Celcuity Inc. on SEC Form 13F: 295.7K shares, about 0.60% of the company, worth $23.5M at the end of Q3 2026. At today's price that stake is worth $19.0M, about 0.01% of PFE's own market value.
- Holder
- PFE
- Shares held
- 295.7K
- Stake
- 0.60%
- Value
- $23.5M
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did Celcuity Inc.'s latest earnings release say?
Most important lines
- 1
Prostate-specific antigen (“PSA”) ≥50% decreases from baseline were observed across all dose levels; response rates were 36%, 47% and 67% at the 120-, 180-, and 240-mg gedatolisib dose levels, respectively, in patients with prior exposure to either abiraterone or enzalutamide.
New this quarterNegative tone - 2
The discontinuation rate for gedatolisib due to adverse events was 5% and 4% with the gedatolisib triplet and doublet, respectively, compared to 19% for alpelisib + fulvestrant.
New this quarterNegative tone - 3
In the aggregate, $25.3 million of the $27.4 million SG&A increase related to commercial headcount additions and other activities to support the commercialization of REVTORPYK.
ETF holders
ETFs holding CELC
Top ETF holdersWeight
News & sentiment
What is the news saying about CELC?
CELC rose 1.9% over the month to Nov 13. News tone held between 0 and 76 from Oct 14 to Oct 29, then jumped to 75 on Oct 30.
- Oct 16 -6.3%
- Oct 22 +8.1%same day: Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
- Nov 5 -7.5%same day: Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Technical analysis
How strong is CELC's momentum right now?
On the daily chart CELC ranks at the 11th percentile for momentum against 1,062 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling CELC?
48 of the 70 tracked managers added to CELC in their latest 13F and 21 trimmed. Together they own 32.6% of the company, worth $1.3B. BlackRock and State Street alone hold 10.7%.
- 1BlackRock, Inc.6.47%$252.7M positionNew position last quarter
- 2State Street Corp4.19%$163.5M positionAdded 5.2% last quarter
- $154.4M positionAdded 3.6% last quarter
- 4Morgan Stanley3.12%$121.9M positionNew position last quarter
- $81.7M positionNew position last quarter
- $43.4M positionAdded 6.2% last quarter
- 7FMR LLC (Fidelity)1.10%$42.9M positionAdded 538.8K shares last quarter
- $39.9M positionAdded 1.4% last quarter
- $34.1M positionAdded 65.4% last quarter
- $35.5M positionAdded 0.3% last quarter
Discover more
How has CELC done against its peers?
Over the six months to Nov 13, CELC returned −48.9%. Of the 15 related stocks and ETFs, all did better, led by MRNA at +345.8%.
- 1MRNAModerna, Inc.up 345.8%+394.7 pts
- 2ARKGARK Genomic Revolution ETFup 44.7%+93.6 pts
- 3AMGNAmgen Inc.up 38.4%+87.3 pts
- 4ROIVRoivant Sciences Ltd.up 35.8%+84.7 pts
- 5REGNRegeneron Pharmaceuticals, Inc.up 33.0%+81.9 pts
- 6RPRXRoyalty Pharma plcup 29.4%+78.3 pts
- 7XLVHealth Care Select Sector SPDR Fundup 28.7%+77.6 pts
- 8GILDGilead Sciences, Inc.up 27.3%+76.2 pts
- 16CELCThis stockdown 48.9%